Concepedia
Statistics
Publications
8
Citations
1.9K
H-Index
Active since
2009
Affiliations
Tufts Medical Center(Current)
Massachusetts General Hospital
Harvard University
Boston University
Dana-Farber/Harvard Cancer Center
Erin M. Coffee is an author at Tufts Medical Center specializing in molecular oncology, medicine, and oncogenic signaling pathways.
Publications per year
2009–2014
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke et al. · Cancer Discovery · 2012 · 1K citations · Full text
Medicine, Oncology, Pharmacology +17
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata et al. · Cancer Cell · 2012 · 379 citations · Full text
Medicine, Cancer Biology, Oncology +17
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
Jatin Roper, Michael P. Richardson, Wei Vivian Wang et al. · PLoS ONE · 2011 · 140 citations · Full text
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Anthony C. Faber, Erin M. Coffee, Carlotta Costa et al. · Cancer Discovery · 2013 · 127 citations · Full text
Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of <i>BRAFV600E</i> Colorectal Cancer
Erin M. Coffee, Anthony C. Faber, Jatin Roper et al. · Clinical Cancer Research · 2013 · 78 citations · Full text
1–5 of 8